Skip to Main Content

The biopharma industry is racing to respond to the novel coronavirus pandemic. But the industry has also suffered massive disruptions as shelter-in-place orders have brought some projects screeching to a halt.

A slew of pharmaceutical and biotech companies have suspended their clinical trials in recent weeks. Brian Skorney, a senior biotech research analyst at investment bank Baird, spoke with STAT about how the pandemic has affected the industry and how those disruptions will shape drug development in the months and years to come.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.